Drug repurposing by integrated literature mining and drug-gene-disease triangulation.

Drug design is expensive, time-consuming and becoming increasingly complicated. Computational approaches for inferring potentially new purposes of existing drugs, referred to as drug repositioning, play an increasingly important part in current pharmaceutical studies. Here, we first summarize recent developments in computational drug repositioning and introduce the utilized data sources. Afterwards, we introduce a new data fusion model based on n-cluster editing as a novel multi-source triangulation strategy, which was further combined with semantic literature mining. Our evaluation suggests that utilizing drug-gene-disease triangulation coupled to sophisticated text analysis is a robust approach for identifying new drug candidates for repurposing.

[1]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[2]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[3]  Hao Ye,et al.  Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.

[4]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[5]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[6]  O D Saugstad,et al.  [D-penicillamine: old drug, new indication? D-penicillamine reduced pulmonary hypertension induced by free radicals]. , 1992, Orvosi hetilap.

[7]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[8]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[9]  P. Pandolfi,et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. , 1998, The New England journal of medicine.

[10]  Yongcui Wang,et al.  Drug Repositioning by Kernel-Based Integration of Molecular Structure, Molecular Activity, and Phenotype Data , 2013, PloS one.

[11]  Vijay S. Pande,et al.  SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery , 2013, PloS one.

[12]  Ying Zhang,et al.  New drug candidates and therapeutic targets for tuberculosis therapy. , 2006, Drug discovery today.

[13]  Sander R. Dubovy,et al.  SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[14]  Xia Jing,et al.  Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis , 2012, Clinical Cancer Research.

[15]  M. Schroeder,et al.  Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[16]  N. Simon,et al.  Ropinirole for antidepressant-induced sexual dysfunction , 2002, International clinical psychopharmacology.

[17]  Min-Seok Kwon,et al.  IDMap: facilitating the detection of potential leads with therapeutic targets , 2008, Bioinform..

[18]  S. Hebbring The challenges, advantages and future of phenome-wide association studies , 2014, Immunology.

[19]  M. Wong,et al.  In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug , 2015, PloS one.

[20]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[21]  A. J. Crowle,et al.  Chlorpromazine: a drug potentially useful for treating mycobacterial infections. , 1992, Chemotherapy.

[22]  Joseph Mullen,et al.  Mining integrated semantic networks for drug repositioning opportunities , 2016, PeerJ.

[23]  Xin Wu,et al.  Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity. , 2014, Molecular bioSystems.

[24]  Alexander A. Morgan,et al.  Supplementary Materials for Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011 .

[25]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[26]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database's 10th year anniversary: update 2015 , 2014, Nucleic Acids Res..

[27]  Robert M. Plenge,et al.  Disciplined approach to drug discovery and early development , 2016, Science Translational Medicine.

[28]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[29]  W. Ondo,et al.  Ropinirole for restless legs syndrome , 1999, Movement disorders : official journal of the Movement Disorder Society.

[30]  Miguel Viveiros,et al.  Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. , 2007, The Journal of antimicrobial chemotherapy.

[31]  Egon L. Willighagen,et al.  The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo-and Bioinformatics , 2003, J. Chem. Inf. Comput. Sci..

[32]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[33]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[34]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[35]  Simon M Lin,et al.  Opportunities for drug repositioning from phenome-wide association studies , 2015, Nature Biotechnology.

[36]  H P Koeffler,et al.  Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. , 2012, Oncology letters.

[37]  Asher Mullard,et al.  2010 FDA drug approvals , 2011, Nature Reviews Drug Discovery.

[38]  Fu Lm,et al.  Thalidomide and tuberculosis. , 2002 .

[39]  Sanjay Joshua Swamidass,et al.  Mining small-molecule screens to repurpose drugs , 2011, Briefings Bioinform..

[40]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[41]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.